News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|March 16, 2021

Risky Business: The Higher Risk of Nonsuicidal Self Injury in Bisexual Individuals

Author(s)Brendan J. Dunlop

Bisexual individuals are at 4.5 to 6 higher risk of self harming than heterosexual individuals, according to this online study.

Brendan Dunlop talks about the self-harm risks and nuanced needs of bisexual individuals. For updates on the study, follow them on Twitter here.

Brendan J. Dunlop is a clinical psychologist in training at the University of Manchester, UK, and co-investigator on the Self-Injury in Young Bisexual People - a Longitudinal Investigation (SIBL) study.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

tech landscape

Requiring AI-Driven Suicide Risk Stratification in Emergency Settings: Helpful or Risky?

BySarah Cheema, MD,Andrew Canto, MD,Nicolas Badre, MD

July 21st 2026

1 expert is featured in this series.

Take-Home Messages: Clinical Confidence in Transitioning Patients to Cobenfy

ByDavid Walling, PhD

July 8th 2026

1 expert is featured in this series.

Managing Tolerability and Setting Patients Up for Success with Cobenfy

ByDavid Walling, PhD

July 1st 2026

NongEngEng/Adobe Stock

Signal in Noise: How Can Artificial Intelligence Benefit Psychiatric Practice?

ByJoseph F. Goldberg, MD,Roy Perlis, MD

June 30th 2026

schizophrenia

Assessment of Suicide Risk in Individuals With Schizophrenia

ByCarla Kotzé, PhD, MMed, MPhil, FCPsych,Johannes Lodewikus Roos, MD, DSc, MMed, FCPsych

June 17th 2026

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Trending on Psychiatric Times

Remlifanserin for the Treatment of Alzheimer Disease Psychosis Receives FDA Fast Track Designation

Future DSM Plans Overlook Core Problem of Validity

Crisis Management and Care Planning in Schizophrenia

Optimizing Care Transitions and Access in Schizophrenia Management

Assessing Antipsychotics as Antidepressant Adjuncts